| Autor: |
Nwabuko, Ogbonna Collins, John, Rapheal Edoka |
| Předmět: |
|
| Zdroj: |
Onkologia i Radioterapia; 2019, Issue 2, p46-51, 6p |
| Abstrakt: |
Multiple myeloma (MM) is the second commonest hematologic malignancy of public health importance after non-Hodgkins lymphoma. It has been found to occur commonly among the Blacks. Unfortunately, there is poor case ascertainment of the disease in Low-Income Countries (LICs) such as those in sub-Saharan Africa. The few newly diagnosed MM do not have access to a complete assessment tests making it difficult to stratify them and decide appropriate target therapy for their treatment. In this report, a 54-year old female who was diagnosed MM in Nigeria underwent risk stratification 9 years after. A complete assessment test showed a Stage III-A IgA-kappa FLC myeloma with 4;14 translocations and chromosome 13 deletion. She was on thalidomide-dexamethasone; melphalanprednisolone and bortezomib-dexamethasone combination regimens at different cycles. She went into progression (cord compression fracture) 7 years after diagnosis She subsequently underwent laminectomy, but was lost to follow-up 3 years after. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
